Clay Siegall, Ph.D., has served as a member of our board of directors since May 2021. Dr. Siegall currently serves as President, Chief Executive Officer, and Chairman of the Board of Seagen Inc. (formerly Seattle Genetics, Inc.). Dr. Siegall co-founded Seagen in 1998. Prior to co-founding Seagen, Dr. Siegall worked for the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997, most recently as a Principal Scientist. From 1988 to 1991, Dr. Siegall was a Staff Fellow/Biotechnology Fellow at the National Cancer Institute, National Institutes of Health. Dr. Siegall has served as the Chairman of the Board for Umoja, a private biotechnology company since October 2021. Previously, Dr. Siegall served as a director of Ultragenyx Pharmaceuticals, Inc. from January 2014 to June 2021. Dr. Siegall also served as a director of Alder BioPharmaceuticals, Inc. from November 2005 to October 2019 and as a director of Mirna Therapeutics, Inc. from January 2013 to December 2016. Dr. Siegall received a B.S. in Zoology from the University of Maryland and a Ph.D. in Genetics from George Washington University.